Historique
Article de Périodique
Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002 (2006)
(Prévalence des infections à l'hépatite et au VIH et taux de vaccination chez ls patients débutant un traitement à l'héroïne sous surveillance entre 1994 et 2002)
Auteur(s) :
GERLICH M. ;
GSCHWEND P. ;
UCHTENHAGEN, A. ;
KRAMER, A. ;
REHM, J.
Année
2006
Page(s) :
545-549
Langue(s) :
Anglais
Refs biblio. :
34
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus mots-clés
HEPATITE
;
VIH
;
TRAITEMENT DE MAINTENANCE
;
DISTRIBUTION CONTROLEE
;
HEROINE
;
ENQUETE
;
PREVALENCE
Thésaurus géographique
SUISSE
Résumé :
Background: Hepatitis C virus (HCV) remains very prevalent in injection drug users (IDUs). In spite of recommended vaccinations against hepatitis A virus (HAV) and hepatitis B virus (HBV), many IDUs remain susceptible to HAV and HBV. Study population and methods: ?Patients entering heroin-assisted treatment between 2000 and 2002 (N = 210) were compared for infectious disease status with patients entering this treatment in 1998 (N = 243) and between 1994 and 1996 (N = 1035). Infection status was determined with the aid of questionnaires and blood tests for antibodies against HAV, HBV core antigen, HCV and HIV. Results: ?In the cohort 20002002 78.3% of the patients were HCV positive, 53.3% were HBV positive, 41.2% were HAV positive and 12.6% were HIV positive. In comparison to the cohorts entering the heroin- assisted treatment at an earlier time, there was a significant reduction of HBV and HAV infections, but not of HCV and HIV infections. 15.6% of the patients entering between 2000 and 2002 were vaccinated against HBV and 10.3% against HAV. 31.1% of patients at entrance were susceptible for HBV and 48.5% for HAV. In comparison to patients entering treatment in 1998 there was no significant increase in patients who were vaccinated against HBV. Conclusions:This data illustrates the need for improving HCV prevention and more consequent vaccination against HBV and HAV in IDUs.
Affiliation :
Research Institute for Public Health and Addiction, Zürich, Switzerland